Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Abbott Laboratories (ABT) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareABT

Latest price · Nov 20, 2026 $104.17 +0.3% on the day · -14.4% over 12 months 52-week range $81.98 – $126.55
Get ABT alerts
Open-market purchases4 insiders$4.4M · last 12 months
Insiders selling7last 12 months
Reported sales$47.9M0 of 12 recent sales pre-planned (10b5-1)
In 15 seconds

Some insider buying ($4.4M), but sales were much larger ($47.9M) over the same 12 months.

Past insider buys here: 3 of 5 beat the S&P 500 over the next 90 days. See each one ↓

Label: Mixed: buying, heavier selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 26, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Mary K. Moreland, President sold 3,500 shares at $116.00 ($406K).

Trade date
Nov 5, 2026
Disclosed to the SEC
Nov 6, 2026
Type
Sale (code S)

Read the original SEC filing ↗All ABT insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

ABT insider transactions (Form 4)

Open-market purchases and sales. 44 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 6SEC Mary K. MorelandPresident Sell 3,500100,791 held (−3%) $116.00 $406K -10.2% —
Sep 3SEC John A. McCoy Jr.President Sell 2724,549 held (−0%) $109.54 $3K -4.9% —
Aug 27SEC Robert B. FordCEO, Chair Sell 218,535486,758 held (−31%) $115.57 $25.3M -9.9% —
Aug 27SEC Robert B. FordCEO, Chair Sell 180,297306,461 held (−37%) $116.19 $20.9M -10.3% —
Aug 13SEC Louis H. MorronePresident Sell 5,85070,724 held (−8%) $109.83 $643K -5.2% —
Jun 18SEC John G. StrattonDirectorFirst buy Buy 2,00023,319 held (+9%) $86.82 $174K +20.0% —
Apr 28SEC Daniel J. StarksDirectorPast buys 1/2 beat S&P Buy 10,0006,751,103 held (+0%) $92.65 $927K +12.4% 35
Apr 27SEC Philip P. BoudreauCFOFirst buyNew position Buy 2,200new position $91.50 $201K +13.8% —
Mar 3SEC Louis H. MorronePresident Sell 1,14476,843 held (−1%) $115.58 $132K -9.9% —
Mar 3SEC Daniel Gesua Sive SalvadoriPresident Sell 885146,377 held (−1%) $115.58 $102K -9.9% —
Mar 3SEC Eric ShroffPresident Sell 70939,164 held (−2%) $115.58 $82K -9.9% —
Mar 3SEC Mary K. MorelandPresident Sell 613104,291 held (−1%) $115.58 $71K -9.9% —
Mar 3SEC John A. McCoy Jr.President Sell 58524,628 held (−2%) $115.58 $68K -9.9% —
Mar 3SEC Elizabeth C. CushmanEvp, Gc And Secretary Sell 26338,573 held (−1%) $115.58 $30K -9.9% —
Feb 6SEC Daniel J. StarksDirectorFirst buyPast buys 1/2 beat S&P Buy 5,0336,738,817 held (+0%) $108.33 $545K -3.8% 35
Feb 6SEC Daniel J. StarksDirectorFirst buyPast buys 1/2 beat S&P Buy 4,9676,733,784 held (+0%) $109.14 $542K -4.6% 35
Jan 26SEC Robert B. FordCEO, ChairFirst buy Buy 18,800216,203 held (+10%) $107.13 $2.0M -2.8% —
Nov 25SEC Eric ShroffPresident Sell 1,58630,384 held (−5%) $128.02 $203K -18.6% —
Historical context

Similar past setups: not applicable. There aren't enough comparable past cases for ABT's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with ABT in the Research Lab

Pre-set to ABT's latest insider buy of $10K or more (Jun 18, 2026: John G. Stratton, $174K). Tap to change anything.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

ABT closeInsider buyInsider sale
80100120140DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-22EEarnings release filed 2026-04-16EEarnings release filed 2026-07-16EEarnings release filed 2026-10-21Sold $2,958 on 2026-09-02 · John A. McCoy Jr.Bought $173,640 on 2026-05-07 · John G. StrattonBought $201,300 on 2026-04-23 · Philip P. BoudreauSold $203,043 on 2025-11-25 · Eric ShroffSold $406,000 on 2026-11-05 · Mary K. MorelandSold $485,320 on 2026-03-02 · Daniel Gesua Sive Salvadori, Elizabeth C. Cushman, Eric Shroff, John A. McCoy Jr., Louis H. Morrone, Mary K. MorelandSold $642,506 on 2026-08-11 · Louis H. MorroneBought $926,537 on 2026-04-27 · Daniel J. StarksBought $1,087,331 on 2026-02-04 · Daniel J. StarksBought $2,013,967 on 2026-01-23 · Robert B. FordSold $46,204,798 on 2026-08-25 · Robert B. Ford
Bought, 12 months$4.4M
Sold, 12 months$47.9M
Insiders buying4
Insiders selling7

Abbott Laboratories insider trading at a glance (Nov 20, 2026): in the past 12 months, 4 insiders bought $4.4M and 7 sold $47.9M of ABT stock on the open market, including a cluster buy that began Apr 23, 2026; P/E 31.5 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

ABT insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $203K sold (1 trades)Q4 2025Q1 2026: $3.1M bought (3 trades)$3.1MQ1 2026: $485K sold (6 trades)Q1 2026Q2 2026: $1.3M bought (3 trades)$1.3MQ2 2026Q3 2026: $46.9M sold (4 trades)Q3 2026Q4 2026: $406K sold (1 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$406K1
Q3 2026—0$46.9M4
Q2 2026$1.3M3—0
Q1 2026$3.1M3$485K6
Q4 2025—0$203K1

Valuation, profit and volume

P/E (trailing)31.5Sector median 25.0
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit+$77KOn all tracked purchases +1.7%

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 4 Abbott Laboratories insiders reported open-market purchases totaling $4.4M, while 7 insiders reported sales totaling $47.9M. The most recent cluster buy began on Apr 23, 2026, when 3 insiders bought a combined $1.3M. Among insiders with enough purchase history to measure, Daniel J. Starks (Director) has the highest Insider Score at 35. 0 of 12 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ABT earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 21, 2026 +3.0% None +0.1%S&P -0.7% pending
Jul 16, 2026 -0.9% None +12.8%S&P -1.5% +10.5%
Apr 16, 2026 -0.5% None -4.7%S&P +1.5% -12.7%
Jan 22, 2026 -5.0% None -11.0%S&P +0.6% +4.5%
Oct 15, 2025 +0.1% None -3.8%S&P -0.2% +2.3%
Jul 17, 2025 -2.9% None -6.1%S&P +0.5% +6.5%
Apr 16, 2025 -4.4% None +3.8%S&P -2.1% +2.9%
Jan 22, 2025 +3.9% None +5.5%S&P +1.1% +9.5%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

ABT short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 53% of volume sold short2026-08-27: 45% of volume sold short2026-08-28: 36% of volume sold short2026-08-31: 37% of volume sold short2026-09-01: 31% of volume sold short2026-09-02: 56% of volume sold short2026-09-03: 49% of volume sold short2026-09-04: 66% of volume sold short2026-09-08: 57% of volume sold short2026-09-09: 61% of volume sold short2026-09-10: 41% of volume sold short2026-09-11: 31% of volume sold short2026-09-14: 40% of volume sold short2026-09-15: 37% of volume sold short2026-09-16: 55% of volume sold short2026-09-17: 44% of volume sold short2026-09-18: 68% of volume sold short2026-09-21: 37% of volume sold short2026-09-22: 47% of volume sold short2026-09-23: 49% of volume sold short2026-09-24: 43% of volume sold short2026-09-25: 60% of volume sold short2026-09-28: 49% of volume sold short2026-09-29: 43% of volume sold short2026-09-30: 38% of volume sold short2026-10-01: 39% of volume sold short2026-10-02: 39% of volume sold short2026-10-05: 54% of volume sold short2026-10-06: 51% of volume sold short2026-10-07: 25% of volume sold short2026-10-08: 51% of volume sold short2026-10-09: 38% of volume sold short2026-10-12: 43% of volume sold short2026-10-13: 35% of volume sold short2026-10-14: 40% of volume sold short2026-10-15: 40% of volume sold short2026-10-16: 35% of volume sold short2026-10-19: 28% of volume sold short2026-10-20: 54% of volume sold short2026-10-21: 50% of volume sold short2026-10-22: 48% of volume sold short2026-10-23: 36% of volume sold short2026-10-26: 51% of volume sold short2026-10-27: 53% of volume sold short2026-10-28: 43% of volume sold short2026-10-29: 32% of volume sold short2026-10-30: 60% of volume sold short2026-11-02: 57% of volume sold short2026-11-03: 35% of volume sold short2026-11-04: 38% of volume sold short2026-11-05: 38% of volume sold short2026-11-06: 34% of volume sold short2026-11-09: 35% of volume sold short2026-11-10: 31% of volume sold short2026-11-11: 38% of volume sold short2026-11-12: 18% of volume sold short2026-11-13: 26% of volume sold short2026-11-16: 24% of volume sold short2026-11-17: 26% of volume sold short2026-11-18: 33% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 33%20-day average: 38%Prior 2 months: 45%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded ABT

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Sold $15,001 - $50,000 Mar 27, 2026Jul 21, 2026 +1.5%

What happened after ABT insiders bought

Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.

Across all stocks →
FiledInsiderBought7 days30 days90 days
Jun 18, 2026John G. StrattonDirector$174K +5.5%+7.1% vs S&P+15.8%+16.4% vs S&P+15.9%+14.9% vs S&P
Apr 28, 2026Daniel J. StarksDirector$927K -7.1%-8.8% vs S&P-8.1%-14.1% vs S&P+12.1%+8.0% vs S&P
Apr 27, 2026Philip P. BoudreauCFO$201K -5.7%-6.1% vs S&P-7.7%-12.6% vs S&P+13.4%+9.8% vs S&P
Feb 6, 2026Daniel J. StarksDirector$1.1M +1.7%+3.0% vs S&P+1.6%+3.4% vs S&P-21.0%-27.2% vs S&P
Jan 26, 2026Robert B. FordCEO, Chair$2.0M +0.6%+0.2% vs S&P+5.5%+5.4% vs S&P-14.1%-17.7% vs S&P

Insiders at Abbott Laboratories

InsiderBoughtSoldLast filingPast buys beat S&PScore
Robert B. FordCEO, Chair $2.0M $46.2M Aug 27, 2026 0 of 1 —
Daniel J. StarksDirector $2.0M — Apr 28, 2026 1 of 2 35
Louis H. MorronePresident — $775K Aug 13, 2026 — —
Philip P. BoudreauCFO $201K — Sep 3, 2026 1 of 1 —
John G. StrattonDirector $174K — Jun 18, 2026 1 of 1 —
Mary K. MorelandPresident — $477K Nov 6, 2026 — —
Eric ShroffPresident — $285K Mar 3, 2026 — —
Daniel Gesua Sive SalvadoriPresident — $102K Mar 3, 2026 — —
John A. McCoy Jr.President — $71K Sep 3, 2026 — —
Elizabeth C. CushmanEvp, Gc And Secretary — $30K Jun 29, 2026 — —
Kevin T. ConroyDirector — — Sep 25, 2026 — —
Nancy McKinstryDirector — — Apr 28, 2026 — —
Michael O'GradyDirector — — Apr 28, 2026 — —
Sally E. BlountDirector — — Apr 28, 2026 — —
Michael F. RomanDirector — — Apr 28, 2026 — —
Michelle KumbierDirector — — Apr 28, 2026 0 of 1 —
Claire Babineaux-FontenotDirector — — Apr 28, 2026 — —
Darren W. McDewDirector — — Apr 28, 2026 — —
Patricia Paola GonzalezDirector — — Apr 28, 2026 — —
Nita AhujaDirector — — Apr 28, 2026 — —
Jacob A. OrvillePresident — — Mar 25, 2026 — —
Lisa D. EarnhardtPresident — — Mar 3, 2026 — —
Christopher J. ScogginsPresident — — Mar 3, 2026 — —

Board links: companies that share insiders with ABT

Directors and executives who filed Form 4s for ABT and another company in the last 12 months.

See the map →
  • ACNAccenture Nancy McKinstry Director here · Director at ACN · latest filing Nov 17, 2026
  • ADPAutomatic Data Processing Nancy McKinstry Director here · Director at ADP · latest filing Nov 12, 2026
  • ALGNAlign Technology Kevin T. Conroy Director here · Director at ALGN · latest filing Sep 25, 2026
  • GDGeneral Dynamics John G. Stratton Director here · Director at GD · latest filing Sep 18, 2026
  • GEGE Aerospace Darren W. McDew Director here · Director at GE · latest filing May 7, 2026
  • MDLZMondelez International Nancy McKinstry Director here · Director at MDLZ · latest filing May 21, 2026
  • NTRSNorthern Trust Michael O'Grady Director here · CEO, Chair at NTRS · latest filing Nov 5, 2026
  • TDYTeledyne Technologies Michelle Kumbier Director here · Director at TDY · latest filing Apr 28, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

ABT stock: common questions

Are Abbott Laboratories insiders buying ABT stock?

In the past 12 months, 4 insiders reported open-market purchases of ABT worth $4.4M. The latest was Director John G Stratton bought $174K of ABT at $86.82 — first open-market purchase in our records.

Are Abbott Laboratories insiders selling ABT stock?

7 insiders reported sales worth $47.9M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ABT's P/E ratio?

ABT trades at about 31.5 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is ABT's 52-week range?

Over the past year ABT has traded between $81.98 and $126.55. It last closed at $104.17 on Nov 20, 2026.